Motesanib + Gemcitabine + Erlotinib (100 mg QD) |
Motesanib + Erlotinib (150 mg QD) | |||||
---|---|---|---|---|---|---|
Patient Incidence |
Motesanib 50 mg QD (n = 7) |
Motesanib 100 mg QD (n = 8) |
Motesanib 125 mg QD (n = 10) |
Motesanib 75 mg BID (n = 9) |
Motesanib 100 mg QD (n = 7) |
Motesanib 125 mg QD (n = 7) |
Any adverse event, n | 3 | 8 | 9 | 7 | 7 | 6 |
Adverse events of grade 3, na | 0 | 3 | 6 | 3 | 3 | 4 |
Diarrhea | 0 | 1 | 1 | 0 | 2 | 1 |
Nausea | 0 | 0 | 3 | 1 | 0 | 0 |
Vomiting | 0 | 1 | 2 | 0 | 0 | 0 |
Fatigue | 0 | 1 | 0 | 0 | 0 | 2 |
Tumor necrosis | 0 | 0 | 0 | 1 | 1 | 0 |
Deep vein | ||||||
thrombosis | 0 | 0 | 2 | 0 | 0 | 0 |
Abnormal liver | ||||||
function test | 0 | 1 | 0 | 0 | 0 | 1 |
Neutropenia | 0 | 1 | 0 | 0 | 1 | 0 |
Adverse events of grade 4, n | ||||||
Pulmonary | 1 | 0 | 2 | 1 | 0 | 0 |
embolism | 0 | 0 | 2 | 0 | 0 | 0 |
Febrile neutropenia | 1 | 0 | 0 | 0 | 0 | 0 |
Neutropenia | 0 | 0 | 0 | 1 | 0 | 0 |
Adverse events of interest and highest (worst) grade, n | ||||||
Hypertension | 0 | 0 | 0 | 2 | 1 | 2 |
Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 |
Thrombophlebitis (all grade 3) | 0 | 0 | 1 | 0 | 0 | 0 |
Gallbladder toxicity | 0 | 0 | 2b | 0 | 1c | 0 |
Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 |
Hemorrhagic events | 0 | 0 | 1d | 0 | 1e | 0 |
Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 |
Cardiac toxicity (all grade 3) | 0 | 1f | 0 | 0 | 0 | 0 |